About US
Contact us
Position：Home > Phexcom News >
-
Press Release - Agglomix BV site in Tilburg, Netherlands receives EXCiPACT GMP certification2018/5/9
-
Colorcon Inc., Indianapolis site has recently been awarded an EXCiPACT CertificateEXCiPACT asbl is delighted to announce that the Colorcon Inc., Indianapolis sitehas recently been awarded an EXCiPACT Certificate from SGS, one of EXCIPACT’s internationally-recognised Certification B2017/8/18
-
2018 PHEXCOM Events schedulesPHEXCOM Events 2018 Dear VIP members： In order to continuously provide better services to satisfy your needs of market development and communication, we prepare the “PHEXCOM Events 2018” for your re2017/8/8
-
STAR-TECH & JRS SPECIALTY PRODUCTS CO., LTD CHINESE SITE RECEIVESSTAR-TECH & JRS SPECIALTY PRODUCTS CO., LTD CHINESE SITE RECEIVESEXCiPACT GMP CERTIFICATION AS PHARMACEUTICAL EXCIPIENTSUPPLIERSBrussels, 08 June 2017EXCiPACT asbl is delighted to announce that th2017/6/9
-
Good Distribution Practices for Pharmaceutical ExcipientsIPEC Europe is pleased to announce that this important webinar will be held on 22 June 2017, at 14:30 CEST. The IPEC Federation very recently revisedits Good Distribution Practices for Pharmaceutic2017/5/26
-
Shanxi Guangsheng Medicinal Capsule Co., Ltd’s Shanxi Province site has recently been awarded an EXCiPACT Certificate from BV ChinaEXCiPACT asbl is delighted to announce that the Shanxi Guangsheng Medicinal Capsule Co., Ltd’s Shanxi Province site has recently been awarded an EXCiPACT Certificate from BV China, one of EXCiPACT’s i2017/5/17
-
More Glaxo 'musical execs' as Waterhouse tapped to replace ViiV Healthcare CEOThe exec exodus atGlaxoSmithKline is continuing—and so is the rise of women to the company’s top ranks. Monday, the British pharma giantannouncedthat Dominique Limet, head of HIV unit ViiV Healthcare2016/12/6
-
Roche's Gazyva aims to beat blockbuster Rituxan. Can its latest ASH data help?Roche has big plans for its blood cancer med Gazyva, and for good reason: Biosimilars are coming for its top-selling Rituxan, and Gazyva is the drug designed to take its place. Thing is, Gazyva has2016/12/6
-
What's wrong with the drug pricing climate? Ask a different pharma CEO, get a different answerDrugmakers haven’t been shy this week about sharing their views on drug pricing and how pharma should proceed in that arena going forward. Thing is, they don’t all agree. Tensions were on full displa2016/12/5
-
Lilly's Jardiance snags FDA approval for reducing CV risk in Type 2 diabetesEli Lilly got a big boost for its diabetes drug franchise on Friday when the FDA approved its SGLT2 diabetes drug Jardiance to reduce the risk of cardiovascular death in adult patients with Type 2 dia2016/12/5